JCM Webinar | Updates on Cardiac and Vascular Toxicities from Antineoplastic Drugs
the chairs
With the improvements in cancer prognosis thanks to advances in anti-cancer treatment protocols and new targeted therapies and immunotherapies, we are witnessing an increase in survival; however, at the same time, an increase in morbidity has also been observed among cancer survivors as a consequence of the increased cardiovascular adverse effects of anti-cancer drugs.
This is often the consequence of mechanisms that are still partly unknown, which prevent the development of preventative and curative therapies that target the specific cardio- and vasculotoxic effects of anti-cancer therapies.
In this webinar, we will discuss the new frontiers of cardio-oncology research, the mechanisms and implications of hidden cytotoxicity, and the metabolic roots of anthracycline-induced cardiotoxicity. These topics will be covered by world-class experts in the field.
The webinar will be introduced by an opening greeting from Prof. Dr. Rosalinda Madonna, together with the co-chair Prof. Dr. Luca Liberale.
Date: 07 July 2025 at 4:00 p.m. CEST | 10:00 a.m. EDT | 10:00 p.m. CST Asia
Webinar ID: 844 5419 3422
Webinar Secretariat: journal.webinar@mdpi.com
Meet the Event Chairs
Meet Our Speakers
Prof. Dr. Pietro Ameri
Department of Internal Medicine and Medical Specialties – DIMI, University OF Genova, Italy, IRCCS Ospedale Policlinico San Martino, Genova, Italy;
Pietro Ameri, MD, PhD, is an Associate Professor in Cardiovascular Diseases and a Coordinator of the Translational and Clinical PhD program at the University of Genova, Italy. He also leads a translational research unit, the heart failure outpatient program, and the cardio-oncology service at the affiliated IRCCS San Martino Policlinic Hospital.
He is currently the Secretary of the ESC Council of Cardio-Oncology, the local chairperson of the upcoming ESC 2025 Cardio-Oncology Conference, and a Member of the Scientific Committee on Basic & Translational Research of the ESC Heart Failure Association.
He is the Cardiovascular Oncology Section Editor of the Journal of Thrombosis and Thrombolysis and an Associate Editor of the Journal of Cellular and Molecular Medicine.
His primary interests are heart failure and cardio-oncology, especially with respect to the interplay between heart failure, cancer, and cancer treatments. Pietro Ameri's research group includes biologists, biotechnologists, and physicians and is funded by several grants.
His H-index is 38.
Prof. Dr. Peter Ferdinandy
Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary;
Prof. Dr. Péter Ferdinandy has been recognized as a Highly Cited Researcher in 2014, 2017, 2020, 2021, 2022, 2023, and 2024. He has published more than 350 papers and 6 patent families. His Hirsch index is 69. He received his MD in 1991 and his PhD in 1995 at the University of Szeged, Hungary.
He received postdoctoral training at the University of Alberta, Edmonton, Canada, from 1997 to 1999. He became a registered clinical pharmacologist in 1999.
He received his MBA in finance and quality management in 2004 from the Budapest University of Technology and Economics.
He founded the Pharmahungary Group, a group of R&D companies (www.pharmahungary.com) that have been involved in more than 250 drug/medical device development projects since their foundation in the early 2000s.
He was the president of the International Society for Heart Research, European Section, and the chair of the Working Group of Cellular Biology of the Heart of the European Society for Cardiology.
Currently, he is the vice-rector for science and innovations and the director of the Department of Pharmacology and Pharmacotherapy, at Semmelweis University, Budapest (www.semmelweis.hu).
He is the president of the Hungarian Society of Experimental and Clinical Pharmacology (www.huphar.org) and serves as the Editor-in-Chief of the British Journal of Pharmacology.
Prof. Dr. Emilio Hirsch
Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center “Guido Tarone”, University of Torino, Torino, Italy;
Prof. Dr. Emilio Hirsh is a Professor of Cell Biology at the University of Torino Medical School and Director of the Molecular Biotechnology Center. He is an EMBO and ISHR Fellow. His research has shaped our understanding of phosphoinositide 3-kinases (PI3Ks) as multifunctional signaling and scaffolding proteins, with major contributions in cancer, inflammation, metabolic diseases, and heart failure. He has authored over 300 peer-reviewed publications with >30,000 citations and an H-index of 97 (Google Scholar).
He pioneered PI3K isoform-selective targeting, generated the first PI3K- knockout mice, and contributed to the discovery of PI3Kγ inhibitors now in clinical development. He also uncovered key functions of PI3KC2α in endocytosis, primary cilia, mitosis, and cytokinesis (Nature 2013; Cancer Cell 2017; Science 2021).
He is the founder of the biotech company Kither Biotech, and he holds several patents on PI3K-targeted therapies, including compounds in clinical trials. He has received funding from the Human Frontier Science Program, EU FP5-FP6, Leducq Foundation, and AIRC, and he is the recipient of the ISHR Outstanding Scientist Award.
He has served on the Scientific Boards of Celzome AG, DZHK, and AIRC, and was a consultant for Merck-Serono. He has organized several international meetings (Keystone, FASEB, EMBO) and has given >100 invited lectures at major institutions and conferences worldwide.
Editorial boards: Cardiovascular Research (Associate Editor), Frontiers in Oncology, Cancers, Cell Communication & Signaling, Cancers.
Sponsors and Partners
Organizer
On Monday, 7 July 2025, MDPI and Journal of Clinical Medicine organized the webinar entitled "Updates on Cardiac and Vascular Toxicities from Antineoplastic Drugs".
Please find the closing summary by our Chair, Prof. Dr. Rosalinda Madonna, below.
Thank you for attending our webinar on Cardiac and Vascular Toxicity from Antineoplastic Drugs. The webinar covered some of the most current and hot topics in Cardio-Oncology, including the new frontiers of cardio-oncology research addressed by Prof. Pietro Ameri (University of Genoa, Italy), hidden cardiotoxicity of drugs addressed by Prof. Peter Ferdinandy (Semmelweis University, Budapest, Hungary), and doxorubicin cardiotoxicity addressed by Prof. Emilio Hirsch (University of Turin, Italy).
In the first topic, Prof. Ameri outlined quality standards for accurate, reliable, and exploitable clinical and preclinical research on cardiovascular toxicity related to cancer treatment. In the second topic, Prof. Ferdinandy discussed the mechanisms and implications of hidden cardiotoxicity. In the third topic, Prof. Hirsch elucidated the metabolic roots of anthracycline-induced cardiotoxicity and its control through epigenetics and genetics.
We hope to see you at a future event.
The webinar was hosted via Zoom and required prior registration to attend. The full recording can be accessed below. In order to learn about future webinars, you can sign up for our newsletter by clicking “Subscribe” at the top of the page.
Clinical Updates on Cardiac and Vascular Toxicities from Antineoplastic Drugs and Beyond
Guest Editor: Prof. Dr. Rosalinda Madonna
Deadline for Manuscript Submissions: 25 January 2026